David Cory, Eiger BioPharmaceuticals CEO (Eiger via MultiVu)
March 17, 2022 10:12 AM EDTUpdated 01:05 PM
R&D
Coronavirus

A lit­tle biotech crows about its Covid-19 'one and done' PhI­II, caus­ing at least one top an­a­lyst to change his tune as shares soar

John Carroll

Editor & Founder

The big hey­day of mar­ket delir­i­um re­lat­ed to any­thing pos­i­tive in new Covid-re­lat­ed da­ta has pe­tered out as Omi­cron pass­es over, but lit­tle Eiger Bio­Phar­ma­ceu­ti­cals …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA says Ozem­pic, We­govy short­age is over

Kevin Tang's Con­cen­tra tries to dis­rupt pro­posed Ace­lyrin-Alu­mis merg­er

Pfiz­er ends roll­out of Be­qvez, putting an­oth­er dent in he­mo­phil­ia gene ther­a­py field

Mer­ck KGaA tees up changes to lead­er­ship team; Ex-CVS Health CEO joins Ther­mo Fish­er’s board

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times